U.S. Expansion of Synthetic Hypericin Active Ingredient Manufacturing PRINCETON, N.J., Oct. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has established a partnership agreement with Sterling Pharma Solutions (Sterling) to optimize and implement a commercially viable, scalable production technology ...

Core Insights - Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products for rare diseases with unmet medical needs, inviting investors to a webinar on September 18, 2024 [1][2] Company Overview - The company is developing several product candidates in advanced clinical stages, targeting a potential $2 billion in annual global sales [2] - Key product HyBryte™ (synthetic hypericin) is a photodynamic therapy for cutaneous T-cell lymphoma (CTCL), showing positive results in a Phase 3 study and preparing for a follow-up Phase 3 study [2][4] - HyBryte™ has an estimated market potential of approximately $250 million [2] - Other notable assets include SGX302 for psoriasis, with a market potential exceeding $1 billion, and SGX945 for Behçet's Disease, with a Phase 2a study set to begin later this year [2][4] Public Health Solutions - The company has a Public Health Solutions segment, including a heat-stable vaccine platform technology, ThermoVax®, which has received significant non-dilutive government funding [5] - Development programs include vaccine candidates for ricin toxin, filoviruses (Marburg and Ebola), and COVID-19 [5]

Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J., Sept. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Patent Office has granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin". The newly issued patent's claims are dire ...

PRINCETON, N.J., Aug. 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2024. "This is a pivotal time for Soligenix with a great deal of clinical activity and upcoming milestones," stated Christopher J. Schaber, PhD, President and C ...

Table of Contents As filed with the Securities and Exchange Commission on July 24, 2024. Registration No. 333-_________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOLIGENIX, INC. (Exact name of registrant as specified in its charter) (Primary Standard Industrial (State or other jurisdiction of incorporation or organization) Classification Code Number) Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, New Jerse ...

Future Directions: Looking ahead, Dr. Kim highlighted upcoming milestones, saying, "In the short term, we expect to issue results from the IIS as data warrants... Additionally, these initial results are very exciting and build upon the increasing body of positive HyBryte™ data as we move into the 18-week confirmatory FLASH2 study later this year." PRISM MarketView does not provide investment advice. M PRISM M MarketView Highlights from the Q&A: About Soligenix recommendation of any security. PCG may be comp ...

NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView is pleased to announce an exclusive Q&A session with Dr. Ellen Kim, discussing the promising interim results of Soligenix's (Nasdaq:SNGX) HyBryte™ from the ongoing investigator-initiated study (IIS). HyBryte™ (synthetic hypericin) is a novel photodynamic therapy for the treatment of early-stage cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin's lymphoma with no FDA-approved first-line treatments. Highlights from the Q&A: Promising Inte ...

Soligenix Inc. NASDAQ: SNGX, a late-stage biopharmaceutical company, experienced an astonishing surge Tuesday. At the time of writing, the stock had soared nearly 400%. This dramatic increase, accompanied by a substantial rise in trading volume, warrants a closer look at the catalyst behind this movement and the company's fundamentals. This surge comes amidst increasing interest in small-cap stocks, which have seen a resurgence lately. Summer trading favors volatile market moves in low float names and has d ...

Shares of Soligenix (NASDAQ:SNGX) are surging higher by over 300% following an update on the biopharmaceutical company's study of its HyBryte treatment. HyBryte focuses on patients with early-stage cutaneous T-cell lymphoma (CTCL). According to the press release: "Patients have responded positively to HyBryte™ therapy with 75% (3 of the 4 subjects who have completed at least 12 weeks of therapy) already achieving "Treatment Success", as predefined in the study's protocol as ≥50% improvement in their cumulat ...

Loading... U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 50 points on Tuesday. Check This Out: Nvidia To Rally Over 40%? Here Are 10 Top Analyst Forecasts For Tuesday Information technology shares jumped by 0.8% on Tuesday. Top Headline Equities Trading UP Equities Trading DOWN Also Check This Out: How To Earn $500 A Month From PepsiCo Stock Ahead Of Q2 Earnings In commodity news, oil traded down 1% to $81.53 while gold traded up 0.1% at $2,366.50. Euro zone As ...